Marimastat: The clinical development of a matrix metalloproteinase inhibitor

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2913-2922

  Thomas, A L ^a   Steward, W P ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

BB 2516; Clinical development; Marimastat; Metalloproteinase inhibitor

Indexed keywords

ALPHA 2 MACROGLOBULIN; BATIMASTAT; BINDING PROTEIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; COLLAGENASE; CYTOTOXIC AGENT; DOXORUBICIN; ENZYME PRECURSOR; FLUOROURACIL; FOLINIC ACID; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; PROTEINASE INHIBITOR; SCLEROPROTEIN; STROMELYSIN; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR MARKER; UNINDEXED DRUG;

ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; GLIOMA; HUMAN; HUMAN TISSUE; HYPOTHESIS; INCIDENCE; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MYALGIA; NONHUMAN; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; STOMACH CARCINOMA; SYMPTOMATOLOGY; TUMOR VOLUME;

EID: 0033652601     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2913     Document Type: Article

References (35)

1. Changing views of the role of matrix metalloproteinases in metastasis
2. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
3. Matrix metalloproteinase inhibitors in the treatment of cancer
4. Matrix metalloproteinases: Biologic activity and clinical implications
5. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
6. Conversion of a highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor
7. Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
8. Effects of inhibitors of plasminogen activator, serine proteases and collagenase IV on the invasion of basement membranes by metastatic cells
9. A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
10. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in patient-like orthotopic model in nude mice
11. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model
12. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
13. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo
14. Inhibition of the metastic spread and growth of B 16-BL6 murine melanoma by a synthetic matrix metalloproteinase inase inhibitor
15. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
16. Synthetic matrix metalloproteinase inhibitor BB-94 inhibits the invasion of neoplastic human prostate cells in a mouse model
17. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay
18. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
19. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the anti-tumour activity of cisplatin in ovarian carcinoma xenografts
20. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers
21. Combined analysis of studies of the effects of the Matrix Metalloproteinase inhibitor Marimastat on serum tumour markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
22. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
23. A pilot study of the safety and effects of the matrix metalloproteinase inase inhibitor marimastat in gastric cancer
24. Phase I-II study of marimastat (BB-2516) in patients with metastatic melanoma
25. A randomized Phase II pilot trial of adjuvant marimastat in patients with early breast cancer
26. A Phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer
27. Schedules of 5FU and the matrix metalloproteinase, marimastat: A Phase I study
28. A Phase Ib study of concurrent administration of marimastat and gemcitabine in non-resectable pancreatic cancer
29. Pilot pharmacokinetic study of marimastat in combination with carboplatin/paclitaxel in patients with matastatic or locally advanced inoperable non-small cell lung cancer (NSCLC)
30. A Phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer
31. Phase I/II study of combination antiangiogenesis therapy with marimastat, captopril and fragmin
32. A randomised study comparing marimastat to gemcitabine as first-line therapy in patients with non-resectable pancreatic cancer
33. A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma
34. Results of marimastat study 193 in advanced pancreatic cancer
35. Results of marimastat study 131 in glioblastoma multiforme